Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,999,994.00
Award Year:
2011
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI080009-02A1
Award Id:
n/a
Agency Tracking Number:
R44AI080009
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-050
Small Business Information
138 FARBER HALL, 3435 MAIN STREET, BUFFALO, NY, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
145056607
Principal Investigator:
THOMAS CONWAY
(716) 829-2528
thomasc@therapyx.org
Business Contact:
NEJAT EGILMEX
(716) 829-6059
negilmez@acsu.buffalo.edu
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and TPX-7001 achieved a 50-90 % reduction in the severity of multiple disease indicators in mice with advanced IBD. Importantly, co-administration of ATRA with TGF?1 was essential to achieving maximal therapeutic efficacy and disease amelioration was associated with enhanced T-regulatory cell activity in the colon. Phase II work is designed to further optimize therapy protocol in the pre-clinical murine IBD model, establish scale-up manufacturing process and completetoxicology studies leading up to IND filing. In Aim 1, pre-clinical optimization work is completed. To this end, combination TGF?1 and ATRA dosages are optimized first. This combination is then used to identify the optimal therapeutic regimen, determine the ability of treatment to maintain disease remission in the long-term and monitor side-effects. In Aim 2, scale-up process parameters are established to achieve bulk drug production. Batch-to-batch uniformity and shelf-life are determined for the scaled-upproduct. Aim 3 studies are designed to complete toxicokinetics in 2 mammalian species. These studies are performed in collaboration with the Navigators Toxicology Group at Charles River Laboratories. The data obtained in Aims 1-3 are then utilized in thepreparation of an Investigational New Drug (IND) application to the FDA (Aim 4). Successful completion of Phase II studies will facilitate the advancement of TPX-6001/7001 to a Phase I clinical trial in IBD patients. PUBLIC HEALTH RELEVANCE: Currenttherapies for inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis fail a considerable percentage of patients due to ineffectiveness or therapy limiting side effects. TherapyX, Inc. is developing a more advanced drug delivery system that targets Transforming Growth Factor ?-1 and Retinoic Acid to the site of inflammation in the gut thereby reducing systemic side effects. This therapy has the potential to significantly improve morbidity and quality of life of those suffering withIBD.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government